Tag:
Aspen Pharmacare
Latest Headlines
Latest Headlines
More Merck manufacturing cuts on the way
CEOs have been offering up cuts to manufacturing operations as one antidote to sick balance sheets during the most recent round of earnings updates and Merck is among those whittling away.
Aspen to buy Merck API plant in Netherlands to feed expansion
South Africa's Aspen Pharmacare is negotiating to buy an API manufacturing plant in the Netherlands from Merck's MSD unit in Europe to feed its own moves into other parts of the world.
Cipla, Aspen eye joint excursion in Australia
Indian generics specialist Cipla reportedly has hooked up with one of South Africa's biggest drugmakers for an Australian expedition. Aspen Pharmacare, which also happens to be part-owned by GlaxoSmithKline ($GSK), would tap Cipla's drug supply to expand down under, the Business Standard reports, citing sources.
Aspen Pharmacare eyes another $800M in M&A
South Africa's Aspen Pharmacare has posted some strong full-year sales and profits growth, thanks in part to expansion outside its home market. Part of that growth came from its $879 million
India's Indoco signs on to make meds for Aspen
India's Indoco Remedies inked a deal to supply generic products to South Africa's Aspen Pharmacare for sale in the Australian market. Aspen bought Australia-based Sigma Pharmaceuticals' generics
S. Africa mulls state-run pharma to control HIV med costs
South Africa has decided to take HIV drug pricing into its own hands. After years of complaining that the cost of AIDS drugs was too high, the government says it will start a state-run drug company
Big pharma pounces on South Africa
Drugmakers stand at the ready as South Africa pulls out of recession. Ranbaxy Laboratories has opened its second manufacturing plant there, a $30-million facility called the Be-Tabs Pharmaceuticals
Aspen nabs Sigma's drug biz for $804M
Sigma Pharmaceuticals was playing its cards close to the vest last week when it denied a higher buyout offer from South Africa's Aspen Pharmacare. Aspen might not have hiked its offer for the entire
Sigma denies sweetened buyout bid from Aspen
Sigma Pharmaceuticals denied Australian media reports that Aspen Pharmacare Holdings had boosted its buyout offer for the company to 65 cents per share, or $689 million; Aspen's formal bid made last
Report: Watson flirts with Sigma offer
Sigma Pharmaceuticals is reportedly getting a new suitor. The Australian drugmaker has caught the eye of U.S.-based Watson Pharmaceuticals, which is working to expand its presence overseas. Watson
